TriSalus Life Sciences (TLSI) Amortization of Deferred Charges (2024 - 2026)
TriSalus Life Sciences has reported Amortization of Deferred Charges over the past 3 years, most recently at $296000.0 for Q1 2026.
- For Q1 2026, Amortization of Deferred Charges rose 67.23% year-over-year to $296000.0; the TTM value through Mar 2026 reached $1.2 million, up 23.17%, while the annual FY2025 figure was $766000.0, 26.82% up from the prior year.
- Amortization of Deferred Charges for Q1 2026 was $296000.0 at TriSalus Life Sciences, up from -$34000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $766000.0 in Q2 2025 and troughed at -$34000.0 in Q4 2025.
- A 3-year average of $278125.0 and a median of $232000.0 in 2024 define the central range for Amortization of Deferred Charges.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 223.21% in 2025 and fell as far as 114.98% in 2025.
- Year by year, Amortization of Deferred Charges stood at $227000.0 in 2024, then plummeted by 114.98% to -$34000.0 in 2025, then skyrocketed by 970.59% to $296000.0 in 2026.
- Business Quant data shows Amortization of Deferred Charges for TLSI at $296000.0 in Q1 2026, -$34000.0 in Q4 2025, and $200000.0 in Q3 2025.